-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
-
Summary
-
Halozyme Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Operating Activities history and growth rate from 2010 to 2023.
- Halozyme Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending March 31, 2024 was $129M, a 48.8% increase year-over-year.
- Halozyme Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2023 was $389M, a 61.8% increase from 2022.
- Halozyme Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was $240M, a 19.8% decline from 2021.
- Halozyme Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2021 was $299M, a 440% increase from 2020.
Net Cash Provided by (Used in) Operating Activities, Annual (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Annual Growth (%)